Year 2021
October 2021


Abstract Title
Switching to Subcutaneous Daratumumab: tolerability, patient experience and cost savings.

A.C.Y. TSO1, Y.L. TAN1, B.Y. SIA1, S.Y. TAN1, K.H. ONG1


Tan Tock Seng Hospital1

Background & Hypothesis

The tolerability of SC Daratumumab in the treatment of plasma cell dyscrasias amongst Asian patients especially of low body weights is unknown.


10 patients (5 females and 5 males) with a mean age of 70.1 years; and a mean weight of 57.6kg received SC Daratumumab between March to July 2021.  Their creatinine clearance ranged from 25-98 ml/min.  Patients received a mean 30.2 doses (range 19-51) of IV prior to switching to SC Daratumumab.  Patients were pre-medicated with oral Dexamethasone, Fexofenadine, prior to each SC Daratumumab.  All patients were monitored for 6 hours after their first dose SC Daratumumab only.


All patients tolerated SC Daratumumab with no adverse effects.  Each patient saved over 4 hours of waiting time and translates to ¬400% increase in chemotherapy chair utilization (¬4,368 hours chair-time per year if our 42 active patients made the switch). Due to a lack of chemotherapy slots, patients are admitted for 240 bed days (costing SGD 109,680) per year for administration of IV Daratumumab (based on 30 new Daratumumab).  Fixed price SC Daratumumab is cheaper for patients who weigh >55kg.  4 patients who opted for SC Daratumumab saved a staggering SGD 87,591 per year.  2 patients who weighed 39.9kg and 49kg tolerated SC Daratumumab as the rest of the cohort.

Discussion & Conclusion

The switch to SC Daratumumab improves resource utilisation, increases patient satisfaction and reduces bed occupancy rate and pressure which is even more important during this COVID-19 pandemic.